ANDA 211531, held by Lupin. Dapagliflozin.
As of Nov 15, 2026, ANDA 211531 (Dapagliflozin), held by Lupin, was first approved by FDA on Apr 6, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 6, 2026 | Original application | Approved | None posted |
| Dapagliflozin5MG · tablet;oral | Dapagliflozin | Rx |
| Dapagliflozin10MG · tablet;oral | Dapagliflozin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters